Kineta Announces Participation at H.C. Wainwright 23rd Annual Global Investment Conference
Kineta Announces Participation at H.C. Wainwright 23rd Annual Global Investment Conference Seattle, WA — (August 30, 2021) Kineta, Inc., a clinical stage biotechnology company focused on the developm ...
Kineta Announces Patent Issuance of U.S. Patent for Composition of Matter of KCP506
Kineta Announces Patent Issuance for U.S. Patent Covering Composition of Matter of KCP506, a Novel Non-opioid Therapy for Chronic Pain Seattle, WA -- (August 10, 2021) Kineta Inc, through its subsidi ...
Kineta Announces Successful Completion of Pre-IND Meeting with the FDA for KVA12.1
Kineta Announces Successful Completion of Pre-IND Meeting with the FDA for KVA12.1 Phase 1/2 clinical studies of the company’s anti-VISTA antibody to commence in mid-2022 Seattle, WA — (July 27, 202 ...
Kineta Announces First Participant Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of KCP506
Kineta Announces First Participant Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of KCP506 Seattle, WA — (July 14, 2021) Kineta Inc, through its subsidiary Kineta Chronic Pain LLC, announce ...
Kineta’s Thierry Guillaudeux Participated on Multiple Panel Presentations During Virtual Symposium on VISTA
Kineta’s Thierry Guillaudeux Participated on Multiple Panel Presentations During Virtual Symposium on VISTA: A New Immunotherapy Approach to Treating Cancer Seattle, WA — (June 24, 2021) Kineta, Inc. ...
Kineta to Participate in “VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond” Virtual Symposium
Kineta to Participate in “VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond” Virtual Symposium Seattle, WA -- (June 7, 2021) Kineta, Inc., a clinical stage biotechnology company focus ...
Kineta Presents New Preclinical Data on its Lead VISTA Antagonist Antibody at the AACR Annual Meeting 2021
Kineta Presents New Preclinical Data on its Lead VISTA Antagonist Antibody at the AACR Annual Meeting 2021 Seattle, WA -- (April 12, 2021) Kineta, Inc., a clinical stage biotechnology company focused ...
Kineta Presents Clinical Study Results of LHF-535 at the International Conference on Antiviral Research (ICAR)
Kineta Presents Clinical Study Results of LHF-535 at the International Conference on Antiviral Research (ICAR) Safety, tolerability and pharmacokinetic profile established in Phase 1 clinical study ...
Kineta Presenting at Multiple Investor Conferences in March 2021
Kineta Presenting at Multiple Investor Conferences in March 2021 Seattle, WA -- (March 3, 2021) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapie ...